BACKGROUND: Much controversy persists regarding the place of statin drugs in the treatment of patients with COPD. This systematic review and meta-analysis sought to determine the clinical efficacy of statin therapy in COPD.
COPD is a progressive illness characterized by poorly reversible airflow limitation, lung function decline, and chronic inflammation. It is currently the fourth leading contributor of morbidity and mortality in the world, which results in increasing socioeconomic and individual disease burden. 1 There is no curative treatment for COPD, and existing medications have not been shown conclusively to reduce the progressive deterioration of lung function seen in many patients. Smoking cessation is a key intervention, but this does not abolish disease progression. 1, 2 Effective therapy aiming for better management of COPD is urgently needed.
Statin drugs are widely used for treating hypercholesterolemia. They function by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. In addition to their lipid-lowering capacity, they also possess anti-inflammatory and immunomodulatory effects. 3 Recent research has shown that they may decrease airway inflammation and reduce the level of systemic inflammatory markers such as C-reactive protein (CRP). 4, 5 With the accumulating evidence that COPD is both a pulmonary/airway and systemic inflammatory disease, the pleiotropic effects of statin drugs may confer potential benefits in patients with COPD. 6 Statin drugs have been reported to reverse the progression of pulmonary emphysema and inhibit airway hyperreactivity in rodent models. 7, 8 Based on the findings, observational studies have been conducted that suggest that statin drugs had positive effects on reducing exacerbation rates and COPD-related mortality. 9, 10 By contrast, results from randomized clinical trials testing the efficacy of statin drugs in a highly selected COPD population are much more controversial, suggesting little benefit. 3, 11 This systematic review and meta-analysis was performed to evaluate the clinical impact of statin therapy compared with placebo in randomized controlled trials (RCTs) in COPD. In addition, we planned subgroup analysis based on inclusion vs exclusion of patients with comorbid cardiovascular disease (CVD), high vs low baseline CRP value, elevated vs normal cholesterol level, and severity of COPD. We believe that this is the first such review.
Methods

Search Strategies
This study was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (registered in the PROSPERO International Prospective Register of Systematic Reviews, CRD42017060594). 12 Relevant articles were identified and selected by searching the databases: MEDLINE (1966 to April 2017), EMBASE (1980 to April 2017), Cochrane controlled trials register (The Cochrane Library Issue 4, 2017), and PubMed (updated to April 2016). Detailed information of our search strategy is provided in e-Appendix 1. We examined the references in relevant articles and conference proceedings. In addition, Internetbased sources of information on the results of clinical trials on statin drugs and COPD were scanned for additional articles. There were no restrictions regarding language or publication date placed on the searches. Both full manuscripts and abstracts were considered.
Inclusion and Exclusion Criteria
Original studies were eligible for inclusion if they met the following criteria: (1) they were randomized and placebo controlled; (2) they evaluated the clinical efficacy of statin treatment in patients with COPD of any severity, defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; (3) there was a dropout rate < 20%; (4) they provided data on at least one outcome of interest; and (5) they used a given patient population only once, and if the same group appeared in other publications, only the most recent or complete report of a clinical trial was incorporated.
Data Extraction
Two independent reviewers (W. Z. and Y. Z.) separately screened the titles and abstracts, performed duplicate checking, and reviewed full articles that met the inclusion criteria. Data were independently abstracted from each identified reference with a predesigned review form, and disagreement was resolved by consensus. We retrieved study design and characteristics, patient clinical characteristics and demographics, intervention information, clinical outcomes, and duration of follow-up. The primary outcomes were exercise tolerance (6-min walk distance) and lung function (FEV 1 % predicted, FEV 1 predicted, and FEV 1 to FVC ratio). Additional outcomes included CRP and pulmonary-related inflammatory markers (median neutrophil percentage in induced sputum), allcause mortality, quality of life, acute exacerbations, drug discontinuation, low-density lipoprotein cholesterol (LDL-C), total cholesterol, and adverse events.
Quality Assessment
We assessed the risk of bias of each fully published trial according to the Cochrane risk of bias tool. The main domains were checked, including random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, attrition bias, selective reporting, and other biases. The judgments were expressed as "low risk," "high risk," or "unclear risk" of bias. Any disagreements were resolved by discussion and consensus.
Statistical Analysis
Data analysis was performed with a random-effects model using Stata/ SE, version 11.0 (StataCorp LLC). For all dichotomous data, the relative risk (RR) and 95% CIs were calculated for each independent study and for the summary statistic, with values of < 1 favoring statin drugs. For studies reporting zero events in a treatment or control arm, we applied a half-integer continuity correction to calculate the RR and variance. 13 The mean difference (MD) and 95% CIs were calculated for continuous data. The RR or MD for each clinical event was considered to be significantly different if the P value was < .05 (two sided). The magnitude of heterogeneity between trials was evaluated using the I 2 statistic, with a value of 50% or more indicating a substantial level of heterogeneity. Publication bias was assessed using the Begg and Egger tests.
We performed subgroup analyses to address the clinical efficacy of statin drugs in trials enrolling patients with concomitant CVD, evidence of systemic inflammation (raised CRP level), elevated cholesterol level, or severe airflow limitation. Sensitivity analyses and meta-regression were conducted to examine the robustness of the findings and explore other important clinical differences among the studies.
Results
Study Description
The study selection process is outlined in Figure 1 . We identified 2,921 citations. From them, 20 potentially eligible RCTs were identified. 4, 5, 11, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Studies were excluded from the systematic review if they did not include patients with COPD as the study population, did not have a completely randomized design, were commentaries and review articles, or were experimental reports in nonhuman species. Ultimately, 10 of the 20 studies were selected 4, 5, 11, [14] [15] [16] [17] [18] [19] [20] ; of those not included, three were excluded because they did not use a placebo control, [21] [22] [23] three were excluded because they used the same data set as another study included in this metaanalysis, [24] [25] [26] one was excluded because it was a post hoc analysis of a large statin/heart failure RCT, 27 one was excluded because one-quarter of the recruited patients did not complete the study, 28 one was excluded because most of the patients did not fulfil the GOLD criteria for COPD, 29 and one was excluded because no outcomes of interest were reported. 30 All the included trials were published as peer-reviewed articles, and all were in English. Table 1 shows the baseline characteristics in each of the individual studies.
Patients
A total of 1,471 patients with COPD were recruited for these 10 trials; 728 were randomized to the statin group and 743 to the control group. Mean age ranged from 49 to 72 years. Across the trials, the proportion of male subjects and current smokers ranged from 52% to 100% and 0% to 81%, respectively. Mean baseline FEV 1 % predicted ranged from 42% to 76%. 4, 5, [14] [15] [16] [17] [18] 20 Four statin drugs were investigated in these trials: simvastatin, atorvastatin, rosuvastatin, and pravastatin.
Trial Quality
Methods of randomization and allocation concealment were adequately addressed in the majority of trials. Among the 10 included studies, nine were either doubleor triple-blind and the remaining one used a single-blind design. 5 All trials clearly stated withdrawal rates, which varied across trials and tended to be slightly lower in the statin treatment group (4.4%) than in the placebo group (5.2%). A summary of the risk of bias assessment is presented in e- Figure 1 .
Clinical Outcomes
Exercise capacity: Figure 2 displays the change in 6-min walk distance, which was studied in five trials. 5, [14] [15] [16] 19 Overall, there was a significant benefit in 6-min walk distance with statin drugs: it was greater by 15.5 m (95% CI, 1.43-29.65 m; P ¼ .03). There was no observed heterogeneity between studies (I 2 ¼ 0%).
Lung function: Data for FEV 1 were available in seven RCTs 5, 11, 15, [17] [18] [19] [20] (Fig 3) . The Improvement in FEV 1 % predicted was numerically but not significantly greater with statin therapy than with placebo (MD, 3.2%; 95% CI, -0.30% to 6.78%; P ¼ .07).
Five studies evaluated the effect of statin drugs on the FEV 1 to FVC ratio 11, [17] [18] [19] [20] (Fig 4) . Statin use was associated with a significant improvement in the FEV 1 to FVC ratio (MD, 2.7%; 95% CI, 0.05 to -5.25%; P ¼ .05). Tests of heterogeneity on all measures of spirometry were not significant (I 2 < 5%). Taken together, our data suggested that statin therapy might improve lung function by a small amount.
Inflammatory status: The effect of statin drugs on CRP was determined in six studies 4, 5, [15] [16] [17] 20 There was a nonsignificant trend in CRP reduction in patients receiving statin drugs compared with those receiving placebo (e -Fig 2) . There was a moderate degree of statistical heterogeneity among these six trials (I 2 ¼ 56.6%).
Three RCTs reported data on neutrophil percentage in sputum. 4, 5, 16 There was no difference between statin and placebo groups (MD, -0.79%; 95% CI, -9.99% to 8.40%; P ¼ .87) (e- Fig 3) . Statistical heterogeneity was significant (I 2 ¼ 82.6%).
Quality of life:
The impact of statin drugs on healthrelated life quality in patients with COPD was evaluated using St. George's Respiratory Questionnaire in three trials 5, 11, 15 (Fig 5) . There was a larger improvement with statin drugs compared with placebo (MD, -8.9; 95% CI, -150 to -2.32; P ¼ .008). Between-trial heterogeneity was not obvious (I 2 ¼ 0%).
All-cause mortality: Four eligible trials that enrolled a total of 1,054 patients reported all-cause mortality. 11, 14, 16, 19 There were 29 deaths among 518 individuals in the treatment groups and 31 deaths among 536 individuals in the control groups. There was not a statistically significant difference (RR, 0.97; 95% CI, 0.60-1.58; P ¼ .91) (e- Fig 4) . There was no significant heterogeneity of findings across the studies (I 2 ¼ 0%). Ghobadi (2014) John (2015) Moosavi (2013) Mroz (2015) Overall (I 2 = 0.0%; P = .734) NOTE: Weights are from random effects analysis -130 130 0 chestjournal.org Drug safety: As expected, statin therapy was associated with greatly reduced serum LDL-C and total cholesterol levels (data not shown), which confirmed good compliance with statin use in study participants. Furthermore, the withdrawal rate and incidence of serious adverse events were comparable between the statin and placebo groups (data not shown).
Publication bias: There was no obvious evidence for publication bias, as detected by the Begg and Egger tests.
Subgroup Analysis
Cardiovascular comorbidity: Statin drugs improved exercise tolerance in participants from the trials enrolling patients with COPD with cardiovascular comorbidities, as evidenced by a significantly increased 6- 
Systemic inflammation:
We conducted a subgroup analysis according to baseline CRP levels, since the efficacy of statin drugs in reducing inflammation has been shown to be related to baseline CRP levels. 17 In patients with COPD with higher mean baseline CRP levels (baseline CRP value > 3 mg/L), the statin-treated patients had a numerically better improvement in FEV 1 % predicted (MD, 4.41%; 95% CI, -0.52% to 9.33%; P ¼ .08; I 2 ¼ 0%) and a significantly better Ghobadi (2014) Lee (2009) Lee (2008) Moosavi (2013) Mroz (2015) Neukamm (2015) Overall (I 2 = 0.0%; P = .943) NOTE: Weights are from random effects analysis -18 18 0 further strengthened by another subgroup analysis based on the efficacy of statin drugs in reducing systemic inflammation, which showed that they ameliorated the lung function parameters only in subjects from trials reporting decreased CRP levels after treatment.
Cholesterol level: A subgroup analysis was performed to test whether the benefits from statin drugs were mediated through their lipid-lowering capacity. In studies conducted in the subjects with higher baseline LDL-C levels (baseline LDL-C value > 120 mg/dL), a significant benefit was seen for FEV 1 % predicted (MD, 3.82%; 95% CI, -0.43% to 8.08%; P ¼ .08; I 2 ¼ 0%)
and FEV 1 to FVC ratio (MD, 3.61%; 95% CI, 0.86%-6.36%; P ¼ .01; I 2 ¼ 0%). This effect was not seen in studies conducted in patients with lower baseline LDL-C levels.
Disease severity: Baseline FEV 1 % predicted had no effect on the outcomes of statin treatment.
Sensitivity Analysis
A sensitivity analysis was performed by using both random-and fixed-effect models, and practically the same outcomes were found (except the result for CRP levels), which significantly favored the statin group when using the fixed-effects model. Restricting our analysis to RCTs that recruited stable patients with COPD only, statin-naive patients, or those with a longer observational period (> 3 months) did not significantly alter the pooled results or any heterogeneity.
Meta-regression Analysis
Meta-regression analysis found that patient number, statin class, methods of blinding (single/double/triple), or observational period had no significant effects on the major clinical outcomes.
Discussion
In this systematic review and meta-analysis, pooled analysis of 10 RCTs to determine the efficacy of statin drugs in treating patients with COPD generated some important observations. First, statin drugs improved exercise tolerance, pulmonary function, and healthrelated quality of life in patients with COPD. Second, patients with COPD with comorbid CVD, increased systemic inflammation, or hyperlipidemia appeared to benefit more from statin therapy than the others of this population. Third, there was no association between statin drugs and survival rate, although only a few trials in this analysis focused on this outcome, and the mean study duration was short.
Other than being the first-line cholesterol-lowering medications for prevention of atherosclerotic CVD, statin drugs have attracted growing interest for treating patients with COPD, with the underlying rationale related to their pleiotropic properties and the disease pathogenesis. The usefulness of various statin drugs at different doses has been determined in both rat and mice models, which reported direct and protective effects on the bronchopulmonary system. 31 Observational studies and a related systematic review support the conclusions from the animal research, showing reduced morbidity and mortality in patients with COPD receiving statin drugs. 9,32-34 By contrast, the largest prospective statin-COPD study (the Simvastatin Therapy for Moderate and Severe COPD [STATCOPE] trial) suggested that simvastatin did not reduce the exacerbation rate and had no effect on lung function or health-related quality of life in patients with COPD. 11 These discordant results led to increasing controversy regarding the important but still unsolved puzzle: Should patients with COPD be prescribed statin drugs unless they have identified lipid levels? Ghobadi (2014) Mroz (2015) Overall (I 2 = 0.0%; P = .430) NOTE: Weights are from random effects analysis -22 22 0 Figure 5 -Summary effects of statin drugs vs placebo on changes in St. George's Respiratory Questionnaire score.
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The current collective evidence suggests a role for statin therapy in several different aspects of COPD-specific outcomes. It also appears that patients with comorbid CVD and higher baseline lipid levels may have greater benefits, including lung function benefits, whereas they had no effects in those with normal LDL-C levels. These observations suggest that patients with COPD at elevated cardiovascular risk might be the appropriate subgroup for statin use. This finding accords with that suggested by Young et al 3 in their STATCOPE critique, suggesting that statin drugs may be indicated in as many as 60% to 80% of patients with COPD who have high cardiovascular risk and who have been historically undertreated with statin therapy, leading to poor outcomes in this "unhealthy nonuser" group. This may explain the discrepancy between the results of our analysis and that of the STATCOPE trial, since in that study, patients who met the indications for statin use based on their cardiovascular risk profiles were excluded.
COPD is increasingly recognized as a systemic disease that affects not only airways and lung but also the cardiovascular system. 35, 36 There appears to be a close relationship between COPD and an increased incidence of CVD. 37 A pooled analysis of two large epidemiologic research studies recruiting more than 20,000 adults reported that the prevalence of CVD in patients with COPD was more than two times higher than in people without. 38 Furthermore, a substantially high cardiovascular mortality rate in patients with COPD has been observed, particularly in those with mild and moderate airflow limitation. 39 In one of the largest COPD trials, cardiovascular events were responsible for 27% of the deaths compared with 35% due to respiratory causes. 40 Since statin drugs have been proven to reduce morbidity and mortality from CVD through inhibiting cholesterol biosynthesis, it is reasonable to assume that patients with COPD with concomitant CVD or hyperlipidemia would benefit from therapy with statin drugs.
Unexpectedly, we found that statin drugs appear to possess an ability to improve lung function in patients with COPD, which implies a direct benefit of statin drugs on the pulmonary system. In support of this conclusion, previous studies identified a comparable decrease in mortality in patients with COPD with both high and low cardiovascular risk, which also suggests a positive effect of statin drugs outside their cardiovascular-protective effects. 32 More interestingly, the subgroup analyses showed that statin drugs appeared to exert their protective effect on pulmonary function only in patients with higher baseline CRP value. A plausible explanation for this phenomenon might be that statin-derived benefits may be primarily confined to a COPD population with coexisting systemic inflammation. Previous research has reported a correlation between a change in CRP level, one of the most sensitive markers of inflammation, and improved clinical outcomes in patients with COPD with statin drug use. 17 Our data suggest that since statin drugs may downregulate inflammation only in patients with concomitant CVD or hyperlipemia, the inclusion of patients without these characteristics in studies may mask possible treatment effects. Exclusion of cardiovascular comorbidity that is normally associated with coexisting systemic inflammation could have masked the potential pulmonary benefits of statin drugs in the STATCOPE trial. Taken together, these observations lead to the hypothesis that the underlying mechanism of beneficial effects in patients with COPD could be a result of inhibition of systemic inflammation by statin drugs.
Unlike the results of observational studies, we showed no effects of statin therapy on mortality in patients with COPD, 1,10 but the patient cohorts in the RCTs were small and the study periods were short, so the long-term effects of statin drugs on life expectancy in the COPD population remained unclear.
Although our findings suggested more prominent benefits from statin therapy in patients with COPD and CVD, evidence of systemic inflammation, or hyperlipidemia, it should be recognized that these three factors are commonly present in individuals with COPD and are indications for statin use regardless of the presence of COPD. 41 Although this study demonstrated potential benefits of statin drugs on lung function, a diagnosis of COPD is not in itself an indication for the routine use of statin drugs. Equally, COPD is not a contraindication to statin treatment, so patients with COPD should be evaluated comprehensively for CVD and cardiovascular risks to identify those in whom statin therapy is warranted. The data from this analysis suggest that by identifying patients who meet current indications for statin drugs, those with COPD might also benefit through their effects on lung function and exercise capacity.
Limitations
This systematic review and meta-analysis has limitations. First, the overall study size of the contributing studies was small. Second, several important specific outcomes of COPD, including acute exacerbations, could not be analyzed due to a lack of trials reporting such outcomes. Third, although this study highlighted a statin-induced benefit in trials recruiting participants with comorbid CVD, only some of them enrolled, 100% of whom had both COPD and CVD. Future studies with rigorously predefined patient characteristics are warranted to better understand the potential benefits associated with statin drug use. Fourth, despite generally similar demographic characteristics and minimal evidence of heterogeneity among these RCTs, some confounding factors such as type of statin with different doses might have caused potential bias and made it difficult to analyze the primary intervention of interest. However, the inclusion of only randomized studies with a placebo-controlled design and the use of a random-effects model might be helpful to mitigate some of the possible study heterogeneity. Our attempts to investigate sources of heterogeneity through sensitivity analysis and meta-regression did not identify any factors significantly associated with treatment effect size. All these approaches support the robustness of this analysis; however, the influences of unmeasured covariates cannot be completely ruled out.
Conclusions
This systematic review and meta-analysis showed that statin drugs might improve exercise tolerance, lung function, and health-related quality of life in patients with COPD, particularly those with comorbid CVD, elevated systemic inflammation, or hyperlipidemia. The findings support routine cardiovascular risk assessment in the COPD population to identify patients who have a cardiovascular indication for statin drug treatment, since it might also bring direct benefits to the pulmonary system. Finally, we believe that our observations justify a large RCT to test the hypotheses generated by this systematic review.
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